Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
2001 1
2003 1
2004 3
2005 1
2006 3
2007 7
2008 2
2009 2
2010 1
2011 2
2012 5
2013 2
2014 4
2015 3
2016 5
2017 3
2018 3
2019 3
2020 3
2021 5
2022 1
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Hypereosinophilic Syndrome.
Curtis C, Ogbogu P. Curtis C, et al. Clin Rev Allergy Immunol. 2016 Apr;50(2):240-51. doi: 10.1007/s12016-015-8506-7. Clin Rev Allergy Immunol. 2016. PMID: 26475367 Review.
This entity has been recognized for decades, with early studies identifying distinct groups of patients with differing symptoms, exam findings, laboratory abnormalities, and prognosis. In the past, these patients were treated with non-targeted immunosuppressive agents, oft …
This entity has been recognized for decades, with early studies identifying distinct groups of patients with differing symptoms, exam findin …
World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2022 Jan 1;97(1):129-148. doi: 10.1002/ajh.26352. Epub 2021 Oct 8. Am J Hematol. 2022. PMID: 34533850 Free article.
After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ hybridization, next generation sequencing gene assays, and flow immunophenotyping …
After exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on morphologic review of the bloo …
The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA, Orazi A, Gotlib J, Reiter A, Tzankov A, Hasserjian RP, Arber DA, Tefferi A. Wang SA, et al. Am J Hematol. 2023 Aug;98(8):1286-1306. doi: 10.1002/ajh.26966. Epub 2023 Jun 7. Am J Hematol. 2023. PMID: 37283522 Review.
This review is to focus on the ICC updates related to these disease entities, illustrated through changes related to morphology, molecular genetics, clinical features, prognosis, and treatment. Two practical algorithms are provided in navigating through the diagnosis and c …
This review is to focus on the ICC updates related to these disease entities, illustrated through changes related to morphology, molecular g …
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W, Gotlib J. Shomali W, et al. Am J Hematol. 2019 Oct;94(10):1149-1167. doi: 10.1002/ajh.25617. Am J Hematol. 2019. PMID: 31423623 Free article. Review.
They include morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ-hybridization, flow immunophenotyping, and T-cell clonality assessment to detect histopathologic or clonal evidence for an acute or chronic hematolymphoid neoplasm. RISK STRATIFIC …
They include morphologic review of the blood and marrow, standard cytogenetics, fluorescence in situ-hybridization, flow immunophenotyping, …
Myeloid neoplasms with eosinophilia.
Reiter A, Gotlib J. Reiter A, et al. Blood. 2017 Feb 9;129(6):704-714. doi: 10.1182/blood-2016-10-695973. Epub 2016 Dec 27. Blood. 2017. PMID: 28028030 Free article. Review.
In contrast, patients with FGFR1 and JAK2 fusion TK genes exhibit a more aggressive course and variable sensitivity to current TK inhibitors, and in most cases, long-term disease-free survival may only be achievable with allogeneic hematopoietic stem cell transplantation. …
In contrast, patients with FGFR1 and JAK2 fusion TK genes exhibit a more aggressive course and variable sensitivity to current TK inh …
Jak-2 positive myeloproliferative neoplasms.
Muxí PJ, Oliver AC. Muxí PJ, et al. Curr Treat Options Oncol. 2014 Jun;15(2):147-56. doi: 10.1007/s11864-014-0279-3. Curr Treat Options Oncol. 2014. PMID: 24627006 Review.
Tyrosine-kinase inhibitors (TKIs) have altered the therapy and monitoring of CML patients and improved both their prognosis and quality of life. In 2005, various groups of investigators described a new point mutation of the gene JAK2 associated to MPNs. Although the presen …
Tyrosine-kinase inhibitors (TKIs) have altered the therapy and monitoring of CML patients and improved both their prognosis and quali …
Myeloid somatic mutation panel testing in myeloproliferative neoplasms.
Ross DM, Thomson C, Hamad N, Lane SW, Manos K, Grigg AP, Guo B, Erber WN, Scott A, Viiala N, Chee L, Latimer M, Tate C, Grove C, Perkins AC, Blombery P. Ross DM, et al. Pathology. 2021 Apr;53(3):339-348. doi: 10.1016/j.pathol.2021.01.003. Epub 2021 Mar 3. Pathology. 2021. PMID: 33674147 Review.
This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative neoplasms: polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic neutrophilic leukaemia, systemic mastocytosis, and c …
This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative ne …
Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
Gotlib J, Akin C. Gotlib J, et al. Semin Hematol. 2012 Apr;49(2):128-37. doi: 10.1053/j.seminhematol.2012.01.007. Semin Hematol. 2012. PMID: 22449623 Review.
We review the pathobiology of these myeloproliferative neoplasms (MPNs) with a focus on the relationship between mast cells and eosinophils, and discuss murine models, which further elucidate how the phenotype of these diseases can be influenced by stem cell factor (SCF) and expr …
We review the pathobiology of these myeloproliferative neoplasms (MPNs) with a focus on the relationship between mast cells and eosinophils, …
Update on CML-Like Disorders.
Cross NCP. Cross NCP. Clin Lymphoma Myeloma Leuk. 2020 Sep;20 Suppl 1:S101-S102. doi: 10.1016/S2152-2650(20)30477-8. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32862848
Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis, clinically heterogeneous entity termed 'BCR-ABL1 negative CML' constituting about 5% of CML cases. ...
Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis …
Deactylase inhibition in myeloproliferative neoplasms.
Mithraprabhu S, Grigoriadis G, Khong T, Spencer A. Mithraprabhu S, et al. Invest New Drugs. 2010 Dec;28 Suppl 1(Suppl 1):S50-7. doi: 10.1007/s10637-010-9590-4. Epub 2010 Dec 3. Invest New Drugs. 2010. PMID: 21127942 Free PMC article. Review.
57 results